Trials / Recruiting
RecruitingNCT05477797
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma: a Prospective, Randomized, Controlled, Multicenter Clinical Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.
Detailed description
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years. Progression-free survival (PFS)was defined as the duration from randomization to the first evidence of disease progression or death from any cause. Overall survival (OS) was defined as the duration from the randomization to death from any cause. The Kaplan-Meier method was employed to plot the survival curves, with the log-rank test to assess the differences.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixazomib DX/Lenalidomide DX | After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly. |
Timeline
- Start date
- 2023-02-16
- Primary completion
- 2026-01-15
- Completion
- 2026-01-15
- First posted
- 2022-07-28
- Last updated
- 2024-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05477797. Inclusion in this directory is not an endorsement.